Market Challenges And Opportunities

Global Hematopoietic Stem Cell Transplantation (HSCT) Market – Drivers

Increasing prevalence of cancer: The increasing prevalence of cancer is expected to propel growth of the global hematopoietic stem cell transplantation (HSCT) market over the forecast period. For instance, in February 2022, according to data provided by the World Health Organization, cancer was a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon, rectum, and prostate cancers. The most common in 2020 (in terms of new cases of cancer) were breast (2.26 million cases); lung cancer (2.21 million cases); colon and rectum (1.93 million cases); and prostate (1.41 million cases).
Increasing geriatric population: The increasing geriatric population is expected to drive the global hematopoietic stem cell transplantation (HSCT) market’s growth over the forecast period. For instance, in October 2022, according to data provided by the World Health Organization, in 2020, Between 2015 and 2050, the proportion of the world's population over 60 will nearly double from 12% to 22%. The share of the population aged 60 years and over will increase from 1 million in 2020 to 1.4 million. By 2050, the world’s population of people aged 60 and older will double (2.1 million). The number of people aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million.

Stringent Rules and Regulation for Hematopoietic Stem Cell Transplantation (HSCT): Factors such as side effects associated with hematopoietic stem cell transplantation (HSCT) and stringnet rules and regulations for hematopoietic stem cell transplantation (HSCT) can hamper growth of the hematopoietic stem cell transplantation (HSCT) market over the forecast period. For instance, in January 2023, the Indian Council of Medical Research (ICMR), provide guidelines for umbilical cord blood banking. In India, the UCB banks are required to comply with the provisions specified under Part X-B and Part XII-D of Schedule F of the Drugs and Cosmetics Act 1940 and Rules 1945 (Amendments 2016). The Indian rules define umbilical cord blood as the whole blood, including hematopoietic progenitor cells collected from placental and/or umbilical cord blood vessels after the umbilical cord has been clamped.

Side effects associated with hematopoietic stem cell transplantation (HSCT)
Strignet rules and regulation for hematopoietic stem cell transplantation (HSCT)

Hematopoietic stem cell transplantation (HSCT) market Report Snapshots